NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023

Neuraxis, INC

Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.
Approximately $2M of total revenue was generated in 2019 and 2020.
Company is conducting clinical trials for four additional pediatric indications: chronic nausea, post-concussion syndrome, chemo-induced nausea, and cyclic vomiting.
CEO Brian Carrico cites growing adoption, non-drug therapy trend, and recently completed IPO funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.